newsfilter
← Latest News
GlobeNewswire·

Crescent Biopharma Announces Grants of Inducement Awards

  • Crescent Biopharma's Compensation Committee approved equity inducement awards consisting of 58,650 option shares for two non-executive employees.
  • The awards were granted on September 8, 2026, to facilitate the employees' acceptance of employment under Nasdaq Listing Rule 5635(c)(4).
  • Each option has a 10-year term with an exercise price of $20.46, matching the closing share price on the grant date.
  • Vesting schedules include one-fourth of the shares on the first anniversary of the start date, followed by monthly vesting of one-forty-eighth thereafter, contingent on continuous service.
  • The grants comply with the terms of the Crescent Biopharma 2025 Employment Inducement Incentive Award Plan.
  • Crescent Biopharma is a clinical-stage oncology company developing a PD-1 x VEGF bispecific antibody & novel antibody-drug conjugates for solid tumors.